|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Research and other | |||||
| Operating costs and expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating costs and expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Change in fair value of derivative liabilities | |||||
| Change in fair value of share payable | |||||
| Change in fair value of convertible notes | |||||
| Loss from extinguishment of debt | |||||
| Loss from issuance of debt | |||||
| Interest expense | |||||
| Foreign currency transaction gain (loss) | |||||
| Total other expense | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Deemed dividend related to warrant modifications | |||||
| Net loss attributable to common stockholders | |||||
| Other comprehensive income (loss) | |||||
| Foreign currency translation adjustment | |||||
| Total comprehensive loss | |||||
| Net loss per share applicable to common stockholders, Basic (in dollars per share) | |||||
| Net loss per share applicable to common stockholders, Diluted (in dollars per share) | |||||
| Weighted average shares used in computing basic loss per share (in shares) | |||||
| Weighted average shares used in computing diluted loss per share (in shares) | |||||
Loading...